All In Biotech

Drug Trial Radar · NCT07948447

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NEO 1306 in Healthy Participants

A Phase 1, First-In-Human, Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NEO-1306 in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
NeolaiaBioIndustry
Sponsor type
Industry
Collaborators
NeolaiaBio Aus Pty Ltd
First posted
Nov 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

NEO-1306 is being developed for the treatment of moderately to severely active inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). This will be the first study - A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NEO-1306 in Healthy Participants.

Conditions

  • IBD (Inflammatory Bowel Disease)
  • Healthy Adult Participants

Interventions

  • NEO-1306Drug

    NEO-1306, single Dose #1

  • NEO-1306Drug

    NEO-1306, single Dose #2

  • NEO-1306Drug

    NEO-1306, single Dose #3

  • NEO-1306Drug

    NEO-1306, single Dose #4

  • NEO-1306Drug

    NEO-1306, single Dose #5

  • NEO-1306Drug

    NEO-1306, single Dose #6

  • NEO-1306Drug

    NEO-1306, Multiple Dose #1, single dose once per day for 14 days

  • NEO-1306Drug

    NEO-1306, Multiple Dose #2, single dose once per day for 14 days

  • NEO-1306Drug

    NEO-1306, Multiple Dose #3, single dose once per day for 14 days

  • NEO-1306Drug

    NEO-1306, Multiple Dose #4, single dose once per day for 14 days

  • NEO-1306 PlaceboDrug

    SAD Placebo

  • NEO-1306 PlaceboDrug

    MAD Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v6.0Time frame: 7 days for SAD and 25 days for MAD

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.